BiotechTube
XyloCor Therapeutics

XyloCor Therapeutics

Philadelphia, United States· Est.
xylocor.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $178.5M

Overview

XyloCor Therapeutics is a private, pre-revenue biotech focused on addressing significant unmet needs in cardiovascular disease, specifically advanced coronary artery disease, using gene therapy. The company's lead candidate, XC001, is in Phase 2 development and aims to promote therapeutic angiogenesis. XyloCor's approach is built on foundational intellectual property from Weill Cornell and is led by a seasoned management team, positioning it to potentially offer a transformative treatment for patients with limited options.

Cardiovascular DiseaseCoronary Artery Disease

Technology Platform

Proprietary adenoviral vector-based gene therapy platform for targeted delivery of angiogenic factors (e.g., engineered VEGF) via epicardial injection, licensed from Weill Cornell Medical College.

Funding History

3
Total raised:$178.5M
Series B$67.5M
Series B$80M
Series A$31M

Opportunities

XC001 targets a large, underserved patient population (hundreds of thousands in the US alone) with refractory angina, representing a multi-billion dollar market opportunity for a first-in-class disease-modifying therapy.
Success could also enable platform expansion into other ischemic conditions like chronic limb-threatening ischemia.

Risk Factors

High clinical and regulatory risk associated with a novel gene therapy in a indication with a history of failed angiogenic trials.
The company is pre-revenue and will require significant additional capital to reach commercialization, facing financial and operational risks related to complex manufacturing and specialized delivery.

Competitive Landscape

XyloCor operates in a niche with limited direct gene therapy competitors for refractory angina, but faces indirect competition from device-based therapies (e.g., spinal cord stimulators, coronary sinus reducers), pharmacological agents, and emerging cell therapies. It must also contend with the historical skepticism in the field towards therapeutic angiogenesis.

More companies in Cell & Gene Therapy →More companies in United States →